The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'


Eisai, Merck take on Bayer's Nexavar with new liver cancer nod for Lenvima.....           FiercePharmaAsia?China?s drug leader crackdown; Astellas? gene therapy deal; Huahai?s problems.....           Days after FDA rejection, Regeneron wins label expansion for Eylea.....           Bristol-Myers Squibb's Opdivo secures a lung cancer niche with small-cell green light.....           Apotex plant in India hit with third warning letter in 4 years.....           GlaxoSmithKline whacks 165 jobs as it closes skincare products plant in Ireland.....           Teva scoffs at whistleblowers' evidence in bid to dismiss kickbacks case.....           Turnaround believer Buffett's big Teva investment sends shares soaring.....           Analyst chastises Mylan?not known for its transparency?for under-the-radar dealmaking.....           Louisiana seeking comments on 'Netflix' model for hepatitis C drugs.....           Depomed joins ranks of scandal-plagued pharmas rehabbing their reputations with a name change.....           Court tosses kickbacks case against Eli Lilly but allows plaintiffs another chance.....           As EpiPens run short, Kaléo boasts it has an available supply of epinephrine injectors.....           Thyroid drugs made with ingredient from banned Chinese plant recalled in U.S......           As biosimilars loom, Roche's Genentech plans to lay off 223 staffers in California.....           'Ask your doctor' pitches from digital ads work almost as well as ones on TV: study.....           Allergan taps Pfizer oncology veteran as CMO for some crucial pipeline help.....           Pfizer joins DOJ probe into claims pharma bribes funded Iraqi terrorists.....           AIDS health group brings Gilead patent skirmish to Supreme Court.....           Boston Scientific expands heart implant TV campaign, treading on anticoagulants' turf.....           Bavarian Nordic secures ?30M loan as it expands plant to bring Imvamune manufacturing entirely in-house.....           NICE cost watchdogs spurn Biogen's pricey Spinraza but leave door open for a deal.....           J&J loses early bid to escape Pfizer's Remicade biosimilars lawsuit.....           Alnylam vows value-based pricing, financial help with $450K Onpattro launch.....           CVS' move to lean on ICER data could mean dramatic shift in drug pricing leverage.....           Roche's Xolair, challenged in asthma, wins 'breakthrough' in food allergies.....           Bavarian Nordic secures ?30M loan as it expands plant to bring Imvamune manufacturing entirely in-house.....           NICE cost watchdogs spurn Biogen's pricey Spinraza, but leave door open for a deal.....           Salix, US WorldMeds eye 2019 push into the mainstream for opioid withdrawal drug Lucemyra.....           Outcome's image rehab rolls on with Nielsen deal for first-ever POC audience tallies.....           Merck, Eisai win FDA approval for Lenvima to treat unresectable HCC.....           Teva, Regeneron?s fasinumab succeeds in phase 3 osteoarthritis trial.....           WuXi AppTec, Cyclica collaborate to advance drug discovery programs.....           Amid pricing spat with U.K. government, Vertex won't ask NICE to approve its new CF drug.....           FiercePharmaAsia?Lenvima growth; China?s drug invite; Samsung?s biologics commitment.....           Amid pricing spat with U.K. government, Vertex declines to submit data on new CF drug to NICE.....           Pfizer's Besponsa, Lilly's Taltz rack up reimbursement wins at NICE.....           Express Scripts? new formulary ejects some drugs once thought 'untouchable': analysts.....           States say Alvogen lawsuit is part of a 'guerilla' war against the death penalty.....           FDA found big problems a year ago at Chinese plant now recalling tainted valsartan.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
 
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
 
 
 
 
Latest news

Professional recognition for Pharmaceutical Science Degrees

The Academy of Pharmaceutical Sciences (APS) is delighted to announce that the pharmaceutical science course at the University of Greenwich has become the first APS accredited course having successfully completed the accreditation process set up by the Academy towards the end of 2017.

This is the first time that a pharmaceutical science course has been accredited in the United Kingdom and it is also, we believe, a world first.

Achieving accreditation gives assurance to students and employers that the course meets the high standards required by the Academy and that these standards will be maintained throughout the 5-year period of accreditation.

APS believes that the accreditation process will raise the profile of pharmaceutical sciences in both academia and industry. The discipline is key in the discovery, development and manufacture of new medicines and as such is central to government initiatives to encourage the pharmaceutical industry to maintain and strengthen its strong base here in the UK.

The Academy will continue to work with other stakeholders to build the science base for the ultimate benefit of patients.

 
 
APS events overview

The APS has developed an exciting and informative programme for our events in 2018.

Don’t forget to make a note of APS@FIP, linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference.

Please take a look at our programme, with event summaries, below:

APS@FIP
7 September 2018 - Hilton Hotel, Glasgow
Linking with the 78th FIP World Congress of Pharmacy and Pharmaceutical Science conference, which will take place in the city from the 2 - 6 September 2018. The theme of this conference in 2018 is 'The Science of Differentiated Medicines'.
To learn more and to register, click here

"5 Years of progress in Oral Biopharmaceutics - IMI OrBiTo project and global biopharmaceutics research"
17 September 2018 - AstraZeneca, Granta Park, Cambridge
The APS is pleased to announce this exciting 2 day meeting to review the progress and advances made by the collaborative IMI OrBiTo project . The OrBiTo project started in October 2012 and following a twelve-month non-cost extension phase will finish in October 2018.
To learn more and to register, click here

OTHER EVENTS IN DEVELOPMENT
Industrial Insights 2019
Developability for Biologicals
Inhaled Workshop
3D Printing meeting
Basic Biopharmaceutics workshop 

Follow us
 
Upcoming Events
APS@FIP
7 September 2018
"5 Years of progress in Oral Biopharmaceutics - IMI OrBiTo project and global biopharmaceutics research"
17 - 18 September 2018
APS Developability Workshop
17 - 18 April 2019
APS Industrial Insights 2019
25 - 26 April 2019
10th APS International PharmSci conference 2019
11 - 13 September 2019
Job Vacancies
View all Vacancies
Advertise your job vacancies
The APS is grateful for the support of:
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.

 

The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351, Fax: 0116 274 7365, Email: info@apsgb.org

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.

Privacy Policy:
For details on the data we collect and how we store and process your data please refer to our Privacy Policy.